Stocktoria
InspireMD, Inc. NSPR
InspireMD, Inc. (NSPR) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $9.0M at a -543.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.29 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.731 |
| Retained earnings / assets | -4.356 |
| EBIT / assets | -0.715 |
| Equity / liabilities | 3.887 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NSPR | InspireMD, Inc. | 3/9 | -10.12 | — | — |
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | 5/9 | -19.57 | — | — |
| MDNC | Medinotec Inc. | 5/9 | — | 74 | — |
| WOK | WORK Medical Technology Group LTD | 4/9 | — | — | -14.4% |
| XAIR | Beyond Air, Inc. | 5/9 | — | — | — |
| IVF | INVO Fertility, Inc. | 4/9 | -19.01 | — | — |
| NXGL | NEXGEL, INC. | 5/9 | -6.91 | — | — |
About InspireMD, Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
FAQ
Is NSPR financially healthy?
InspireMD, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NSPR pay a dividend?
No, InspireMD, Inc. does not currently pay a dividend.
How profitable is NSPR?
In FY2025, InspireMD, Inc. had a net margin of -543.3% and a return on equity of -88.4%.
What is the analyst price target for NSPR?
The average Wall-Street price target for InspireMD, Inc. is $3.67, about 326.4% above the recent price, from 3 analysts.
Is NSPR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on InspireMD, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.